FAQ

2'-cyano-2'-deoxyarabinofuranosylcytosine

Known as: 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine, 2'-cyano-2'deoxy-1-beta-D-arabinofuranosylcytosine, CNDAC 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1991-2018
02419912018

Related topics

Related topics

2 relations

Broader (1)

Cytarabine

Narrower (1)

Nucleoside Analog DFP-10917

Related mentions per year

Related mentions per year

1962-2018
1960198020002020
2'-cyano-2'-deoxyarabinofuranosylcytosine
Cytarabine
Nucleoside Analog DFP-10917

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Phase I/II study of sapacitabine and decitabine administered sequentially in elderly patients with newly diagnosed acute myeloid leukemia.
6587 Background: Sapacitabine is a novel nucleoside analogue with a unique ability to cause irreparable single-strand DNA breaks… (More)
Is this relevant?
2007
2007
Antiproliferative effects of sapacitabine (CYC682), a novel 2′-deoxycytidine-derivative, in human cancer cells
This study assessed the antiproliferative activity of sapacitabine (CYC682, CS-682) in a panel of 10 human cancer cell lines with… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2006
2006
A Phase I study of the oral antimetabolite, CS-682, administered once daily 5 days per week in patients with refractory solid tumor malignancies
The development of nucleoside analogues has had a major impact on cancer therapy. CS-682 is a novel, orally administered… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2005
2005
Molecular basis for G2 arrest induced by 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine and consequences of checkpoint abrogation.
2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine (CNDAC) is a nucleoside analogue with a novel mechanism of action… (More)
Is this relevant?
2004
2004
Anti-neovascular therapy by liposomal drug targeted to membrane type-1 matrix metalloproteinase.
Because membrane type-1 matrix metalloproteinase (MT1-MMP) is expressed specifically on the angiogenic endothelium as well as… (More)
Is this relevant?
2002
2002
Anti-neovascular therapy by liposomal DPP-CNDAC targeted to angiogenic vessels.
We previously reported that liposomalized 5'-O-dipalmitoylphosphatidyl 2'-C-cyano-2'-deoxy-1-beta-D-arabino… (More)
Is this relevant?
2001
2001
2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine: a novel anticancer nucleoside analog that causes both DNA strand breaks and G(2) arrest.
The mechanism of 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine (CNDAC) action was investigated in human… (More)
Is this relevant?
1999
1999
Antitumor activity and novel DNA-self-strand-breaking mechanism of CNDAC (1-(2-C-cyano-2-deoxy-beta-D-arabino-pentofuranosyl) cytosine) and its N4-palmitoyl derivative (CS-682).
We have studied the antitumor activity and the novel DNA-self-strand-breaking mechanism of CNDAC (1-(2-Ccyano-2-deoxy-beta-D… (More)
Is this relevant?
1992
1992
Antitumor activity of a novel nucleoside, 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine (CNDAC) against murine and human tumors.
The antitumor effects of 2'-C-cyano-2'-deoxy-1-beta-D- arabinofuranosylcytosine (CN-DAC), a synthetic 1-beta-D-arabinofuranosyl… (More)
Is this relevant?
1991
1991
Nucleosides and nucleotides. 100. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosyl-cytosine (CNDAC): design of a potential mechanism-based DNA-strand-breaking antineoplastic nucleoside.
 
Is this relevant?